• In recent days, Synchrony expanded its integration with Clover from Fiserv, enabling more than 40,000 health and wellness providers to accept CareCredit payments and process new CareCredit applications directly on Clover devices, while Fiserv also introduced its Unknown Shopper in-store analytics tool and deepened its AI collaboration with Microsoft.
• Together, these developments highlight how Fiserv is using AI and data to turn its Clover and payments platforms into broader customer insight and financing ecosystems for merchants and healthcare providers.
• Next, we’ll examine how this deeper Microsoft AI integration and new data products like Unknown Shopper may influence Fiserv’s investment narrative.

We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Fiserv Investment Narrative Recap

To own Fiserv, you need to believe in its ability to turn its broad payments and software footprint, especially Clover, into higher value, data-driven services while managing execution and margin risks. The latest Synchrony, Microsoft AI, and Unknown Shopper updates support this data and AI-led vision, but do not, on their own, change the key near term catalyst of successfully launching and scaling new products, or the main risk of further execution delays and pressure on organic growth.

Among the recent announcements, the expanded AI collaboration with Microsoft looks most relevant, because it aims to embed “AI inside” Fiserv’s platforms and developer tools, potentially supporting faster product rollouts and more competitive offerings. If this helps shorten development cycles and improves how quickly Fiserv can commercialize analytics products like Unknown Shopper on top of Clover, it could matter for the current concern that new initiatives are not ramping quickly enough versus both guidance and peers.

Yet, against this AI progress, investors should also be aware of the risk that persistent delays in launching or scaling key products could still...

Fiserv's narrative projects $24.7 billion revenue and $5.9 billion earnings by 2028. This requires 5.4% yearly revenue growth and a $2.5 billion earnings increase from $3.4 billion today.

Uncover how Fiserv's forecasts yield a $86.50 fair value, a 27% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members have 21 fair value estimates on Fiserv, ranging from US$50 to about US$231.84, with many clustered between roughly US$68 and US$177. These differing views sit alongside the current concern that slower adoption and execution on new platforms could weigh on the business, so it makes sense to compare several perspectives before forming your own view.

Explore 21 other fair value estimates on Fiserv - why the stock might be worth over 3x more than the current price!

Build Your Own Fiserv Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Fiserv research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Fiserv research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Fiserv's overall financial health at a glance.

Seeking Other Investments?

Our top stock finds are flying under the radar-for now. Get in early:

• These 18 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.